The Food and Drug Administration this week issued guidance intended to clarify the agency’s expectations when electronic health records are used as a source of data in clinical investigations. The guidance applies to clinical investigations of human drugs and biological products, medical devices and combination products, including investigations conducted in clinical practice settings.